Cardiol Therapeutics(CRDL) - 2022 Q4 - Annual Report

In December 2020, Cardiol announced the appointment of CRO Worldwide Clinical Trials ("Worldwide") for its Phase II/III trial in high-risk patients hospitalized with COVID-19. In February 2021, the Corporation received proceeds of $7,879,820 on the exercise of 2,424,560 warrants with an exercise price of $3.25, and $503,068 on the exercise of 201,227 warrants with an exercise price of $2.50. In addition, there were a total of 916,666 stock option exercises, resulting in cumulative proceeds of $2,604,648. Dr ...